Free tool
FAERS Monitor: Fintepla
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212102 or its brand name (Fintepla, Fenfluramine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
5,252
Serious
4,328
82% of reports
Hospitalization
1,529
Death reported
135
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- seizure2,298
- drug ineffective795
- tricuspid valve incompetence722
- off label use610
- decreased appetite593
- somnolence502
- weight decreased491
- mitral valve incompetence424
- fatigue372
- diarrhoea334
- generalised tonic-clonic seizure290
- hospitalisation276
- pneumonia264
- pulmonary valve incompetence259
- insomnia222
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 5 |
| 2006 | 1 |
| 2007 | 6 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 11 |
| 2020 | 44 |
| 2021 | 451 |
| 2022 | 743 |
| 2023 | 602 |
| 2024 | 910 |
| 2025 | 1,357 |
| 2026 | 1,095 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,907 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pulmonary valve incompetenceSignal | 259 | 862.9 | 756.5 | 182,768 |
| tricuspid valve incompetenceSignal | 722 | 400.1 | 372.4 | 261,051 |
| mitral valve incompetenceSignal | 424 | 155.9 | 142.0 | 62,697 |
| seizureSignal | 2,298 | 81.3 | 78.8 | 179,476 |
| generalised tonic-clonic seizureSignal | 290 | 71.4 | 63.8 | 19,728 |
| decreased appetiteSignal | 593 | 10.2 | 9.5 | 4,982 |
| somnolenceSignal | 502 | 10.0 | 9.2 | 4,090 |
| hospitalisationSignal | 276 | 7.2 | 6.4 | 1,477 |
| weight decreasedSignal | 491 | 7.1 | 6.5 | 2,575 |
| insomniaSignal | 222 | 3.3 | 2.9 | 366 |
| pneumoniaSignal | 264 | 3.3 | 2.9 | 419 |
| off label useSignal | 610 | 2.8 | 2.6 | 729 |
| drug ineffectiveSignal | 795 | 2.4 | 2.3 | 702 |
| diarrhoeaSignal | 334 | 2.1 | 1.9 | 190 |
| fatigue | 372 | 1.9 | 1.7 | 168 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.